Described herein are methods for treating disorders that relate to neurons that express the neurokinin-1 receptor (NK-1R) in a subject which comprises administering to the subject an effective amount of the pharmaceutical composition of the non-cleavable conjugate comprising a molecule that is recognized and internalized by the NK-1R, and a molecule that is taken inside the cell to kill or temporarily alter the cell.

The present invention provides chimeric ectolysins useful for selective suppression of certain targeted bacterial species while having little to no effect on closely related non-targeted bacterial species. Specifically, the disclosure provides polypeptides for selective suppression of growth of Staphylococcus aureus and/or S. hominis but not S. epidermidis. Compositions and methods for selective suppression of target bacterial species are also provided.

The present invention provides chimeric ectolysins useful for selective suppression of certain targeted bacterial species while having little to no effect on closely related non-targeted bacterial species. Specifically, the disclosure provides polypeptides for selective suppression of growth of Staphylococcus aureus and/or S. hominis but not S. epidermidis. Compositions and methods for selective suppression of target bacterial species are also provided.

The present disclosure provides an attenuated Nocardia seriolae and its construction method and use thereof, which belongs to the technical field of genetic engineering. In the present disclosure, part or all of the glutamate endopeptidase homologue (GluNS) gene sequence of wild-type Nocardia seriolae is knocked out by means of genetic engineering to construct an attenuated strain with the characterized of good protection to the host. The attenuated strain may not only effectively reduce the pathogenicity of the bacteria, but also retain good immunogenicity. At the same time, the attenuated Nocardia seriolae constructed in the present disclosure may also have the characteristics of high genetic stability and may be used as a vaccine candidate strain for the preparation of a vaccine or other biological products for preventing and treating Nocardiosis.

The present disclosure provides an attenuated Nocardia seriolae and its construction method and use thereof, which belongs to the technical field of genetic engineering. In the present disclosure, part or all of the glutamate endopeptidase homologue (GluNS) gene sequence of wild-type Nocardia seriolae is knocked out by means of genetic engineering to construct an attenuated strain with the characterized of good protection to the host. The attenuated strain may not only effectively reduce the pathogenicity of the bacteria, but also retain good immunogenicity. At the same time, the attenuated Nocardia seriolae constructed in the present disclosure may also have the characteristics of high genetic stability and may be used as a vaccine candidate strain for the preparation of a vaccine or other biological products for preventing and treating Nocardiosis.

The present invention relates to novel subtilase variants exhibiting increased stability and preferably on par or improved wash performance. The variants of the invention are suitable for use in e.g. cleaning or detergent compositions, such as laundry detergent compositions and dish wash compositions, including automatic dish wash compositions. The present invention also relates to isolated DNA sequences encoding the variants, expression vectors, host cells, and methods for producing and using the variants of the invention.

The present invention relates to novel subtilase variants exhibiting increased stability and preferably on par or improved wash performance. The variants of the invention are suitable for use in e.g. cleaning or detergent compositions, such as laundry detergent compositions and dish wash compositions, including automatic dish wash compositions. The present invention also relates to isolated DNA sequences encoding the variants, expression vectors, host cells, and methods for producing and using the variants of the invention.

The present invention relates to processes of recovering oil after liquefaction and/or from thin stillage and/or syrup/evaporated centrate from a fermentation product production process by adding a thermostable protease to the whole stillage, thin stillage and/or syrup.

The present invention relates to processes of recovering oil after liquefaction and/or from thin stillage and/or syrup/evaporated centrate from a fermentation product production process by adding a thermostable protease to the whole stillage, thin stillage and/or syrup.

A therapeutic agent comprising Lon protease, or a variant or active fragment thereof, alpha-hemolysin, or a variant or active fragment thereof, CK1α1, or a variant or active fragment thereof, a c-MYB inhibitor and/or a CEBP-δ inhibitor, for use in therapy, with the proviso that the therapeutic agent does not comprise a bacteria or bacterial supernatant. Methods of production and use thereof.